MannKind Corporation (Nasdaq and TASE: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.
In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >
Matthew J. Pfeffer, CEO/CFO and Raymond W. Urbanski, CMO held an investor conference call on February 3 to update on company developments. To view the slide deck Click Here. To view related FAQs Click Here.
To view the FAQ: Technosphere® licensing agreement announced by MannKind™, January 21, 2016. Click Here